Drugs / HS-10502
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06769425 | May 2025 → May 2026 overdue | female breast carcinoma, gastric cancer, ovarian cancer, prostate cancer +1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05740956 | Jun 2023 → Apr 2026 overdue | breast cancer, colorectal cancer, malignant pancreatic neoplasm, ovarian cancer +1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06769425 ↗ |
| Action | Inhibit | “selective inhibitor” NCT05740956 ↗ |
| Route | Oral | “HS-10502 Tablets，PO，QD” NCT05740956 ↗ |
| Target | PARP1 | “Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor” NCT05740956 ↗ |